Literature DB >> 8721469

Treatment of acute reflex sympathetic dystrophy with DMSO 50% in a fatty cream.

W W Zuurmond1, P N Langendijk, P D Bezemer, H E Brink, J J de Lange, A C van loenen.   

Abstract

Acute Reflex Sympathetic Dystrophy (acute RSD) was defined using a reproducible classification. Elevated temperature of the affected extremity ("calor"), measured by the dorsal side of the observer's hand and mentioned by the patient, pain ("dolor") measured by the Visual Analogue Scale (VAS), redness ("rubor"), edema ("tumor") and limited active range of motion ("functio laesa"), all contributed to the classification system. Patients scoring 4 to 5 positive symptoms were considered to have acute RSD. A prospective, randomized and double blind study was performed in 32 patients, all suffering from acute RSD. In all of these patients the primary injury was the result of a previous accident. One patient was taken out of the study because of his surgery. The study involved treatment with a fatty cream with 50% dimethyl sulfoxide (DMSO, group A), or without DMSO (placebo, group B), both for 2 months. All patients received physiotherapy applied within pain limits. Application of the creams resulted in both groups in an improvement of RSD-scores and VAS-scores after 2 months. However, the improvement of the RSD score in patients of group A (DMSO-group) was significantly (P < 0.01) better compared to group B. The results suggest a certain activity of DMSO 50% cream in patients suffering from RSD and is, therefore, recommendable.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8721469     DOI: 10.1111/j.1399-6576.1996.tb04446.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  31 in total

Review 1.  Pharmacologic therapies for complex regional pain syndrome.

Authors:  Sean Mackey; Steven Feinberg
Journal:  Curr Pain Headache Rep       Date:  2007-02

Review 2.  Management of patients with complex regional pain syndrome type I.

Authors:  D Gatti; M Rossini; S Adami
Journal:  Osteoporos Int       Date:  2016-02-29       Impact factor: 4.507

Review 3.  Complex regional pain syndrome.

Authors:  Frank Birklein
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

Review 4.  [Complex regional pain syndrome: A current review].

Authors:  C Maihöfner
Journal:  Schmerz       Date:  2014-06       Impact factor: 1.107

Review 5.  Testing the validity of preventing chronic regional pain syndrome with vitamin C after distal radius fracture. [Corrected].

Authors:  Sunitha Malay; Kevin C Chung
Journal:  J Hand Surg Am       Date:  2014-09-16       Impact factor: 2.230

6.  Subtractive Protein Profiling of Salmonella typhimurium Biofilm Treated with DMSO.

Authors:  Mohd Fakharul Zaman Raja Yahya; Zazali Alias; Saiful Anuar Karsani
Journal:  Protein J       Date:  2017-08       Impact factor: 2.371

7.  N-Acetyl-l-Cysteine Attenuates Ischemia/Reperfusion Injury-Induced Allodynia and N-Methyl-d-Aspartate Receptor Activation in Rats.

Authors:  Kyung-Hwa Kwak; Dong Gun Lim; Woon Yi Baek
Journal:  Curr Ther Res Clin Exp       Date:  2011-10

8.  Evidence based guidelines for complex regional pain syndrome type 1.

Authors:  Roberto S Perez; Paul E Zollinger; Pieter U Dijkstra; Ilona L Thomassen-Hilgersom; Wouter W Zuurmond; Kitty Cj Rosenbrand; Jan H Geertzen
Journal:  BMC Neurol       Date:  2010-03-31       Impact factor: 2.474

9.  Computer-assisted skin videothermography is a highly sensitive quality tool in the diagnosis and monitoring of complex regional pain syndrome type I.

Authors:  Frank J P M Huygen; Sjoerd Niehof; Jan Klein; Freek J Zijlstra
Journal:  Eur J Appl Physiol       Date:  2004-01-21       Impact factor: 3.078

Review 10.  Regulation of peripheral blood flow in complex regional pain syndrome: clinical implication for symptomatic relief and pain management.

Authors:  George Groeneweg; Frank J P M Huygen; Terence J Coderre; Freek J Zijlstra
Journal:  BMC Musculoskelet Disord       Date:  2009-09-23       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.